Brokerages Set Nkarta, Inc. (NASDAQ:NKTX) PT at $14.33

Nkarta, Inc. (NASDAQ:NKTX - Get Free Report) has been assigned an average rating of "Buy" from the eight ratings firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $14.33.

Several equities research analysts have issued reports on NKTX shares. Stifel Nicolaus cut their price objective on shares of Nkarta from $15.00 to $14.00 and set a "buy" rating for the company in a research report on Thursday, March 27th. Mizuho dropped their price target on Nkarta from $16.00 to $14.00 and set an "outperform" rating for the company in a report on Tuesday, June 10th. HC Wainwright restated a "buy" rating and issued a $18.00 price target on shares of Nkarta in a research note on Thursday, March 27th. Needham & Company LLC lowered their price objective on Nkarta from $11.00 to $10.00 and set a "buy" rating on the stock in a research report on Thursday, May 15th. Finally, William Blair reissued a "market perform" rating on shares of Nkarta in a research report on Thursday, May 15th.

Hedge Funds Weigh In On Nkarta

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Invesco Ltd. bought a new position in shares of Nkarta in the fourth quarter worth $30,000. Sequoia Financial Advisors LLC acquired a new stake in Nkarta during the fourth quarter worth about $31,000. Wealth Enhancement Advisory Services LLC bought a new position in Nkarta in the 1st quarter valued at about $32,000. ProShare Advisors LLC acquired a new position in shares of Nkarta in the 4th quarter valued at approximately $45,000. Finally, Sei Investments Co. acquired a new position in shares of Nkarta in the 4th quarter valued at approximately $57,000. 80.54% of the stock is owned by institutional investors and hedge funds.

Nkarta Stock Performance

NKTX traded up $0.09 during trading hours on Friday, reaching $1.78. The company's stock had a trading volume of 370,412 shares, compared to its average volume of 1,032,207. The company's 50-day moving average is $1.83 and its 200-day moving average is $1.96. Nkarta has a 52 week low of $1.31 and a 52 week high of $8.23. The firm has a market cap of $126.31 million, a PE ratio of -1.18 and a beta of 0.70.

Nkarta (NASDAQ:NKTX - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.01. Equities analysts anticipate that Nkarta will post -1.7 earnings per share for the current fiscal year.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.